Motif Bio appoints Stephanie Noviello as new vice president
MOTIF BIO
£0.01
08:30 29/07/20
Clinical-stage biopharmaceutical company Motif Bio has added former Bristol-Myers Squibb clinical lead Stephanie Noviello to its board to take up the vacant role of vice president, reporting directly to chief medical officer David Huang.
Noviello will be a key contributor to the submission of Motif's European Marketing Authorisation application for its novel investigational antibiotic Iclaprim.
Joining the AIM-quoted group from Bristol-Myers Squibb, Noviello most recently acted as the clinical program lead for its virology unit, focusing on its hepatitis B and C and HIV portfolios.
Huang said, "We are delighted to have Stephanie join Motif. Her strategic insights, experience and leadership in late-stage global clinical trials and the regulatory process, including post-marketing requirements, make her ideally suited for this position."
Following positive results from two Phase III trials, a rolling submission of a New Drug Application for Iclaprim with the US Food and Drug Administration for the treatment of acute bacterial skin and skin structure infections was made, something Motif expects to be completed in the second quarter of 2018.
As of 1200 BST, Motif shares had lost 2.92% to 32.45p.